Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ShantonPharmaGoutData

More Like This

PR Newswire associated0

Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial

The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

PR Newswire associated0

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study